Pemafibrate

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Pemafibrate
Accession Number
DB15212
Type
Small Molecule
Groups
Investigational
Description

Pemafibrate is under investigation in clinical trial NCT03350165 (A Study of Pemafibrate in Patients With Nonalcoholic Fatty Liver Disease (NAFLD)).

Structure
Thumb
Synonyms
Not Available
Categories
UNII
17VGG92R23
CAS number
848259-27-8
Weight
Average: 490.556
Monoisotopic: 490.210386694
Chemical Formula
C28H30N2O6
InChI Key
ZHKNLJLMDFQVHJ-RUZDIDTESA-N
InChI
InChI=1S/C28H30N2O6/c1-3-25(27(31)32)35-23-9-6-8-20(18-23)19-30(28-29-24-10-4-5-11-26(24)36-28)16-7-17-34-22-14-12-21(33-2)13-15-22/h4-6,8-15,18,25H,3,7,16-17,19H2,1-2H3,(H,31,32)/t25-/m1/s1
IUPAC Name
(2R)-2-(3-{[(1,3-benzoxazol-2-yl)[3-(4-methoxyphenoxy)propyl]amino]methyl}phenoxy)butanoic acid
SMILES
CC[C@@H](OC1=CC(CN(CCCOC2=CC=C(OC)C=C2)C2=NC3=C(O2)C=CC=C3)=CC=C1)C(O)=O

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

References

General References
Not Available
External Links
ChemSpider
9700824
BindingDB
50214899
ChEMBL
CHEMBL247951
PDBe Ligand
P7F
Wikipedia
Pemafibrate
PDB Entries
6l96

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2Active Not RecruitingTreatmentDyslipidemia1
2Active Not RecruitingTreatmentNon-Alcoholic Fatty Liver Disease (NAFLD)1
3Active Not RecruitingPreventionDyslipidemia / Type2 Diabetes1
3TerminatedPreventionDiabetic Macular Edema (DME) / Diabetic Retinopathy (DR)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0212 mg/mLALOGPS
logP5.22ALOGPS
logP5.79ChemAxon
logS-4.4ALOGPS
pKa (Strongest Acidic)3.94ChemAxon
pKa (Strongest Basic)0.39ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area94.26 Å2ChemAxon
Rotatable Bond Count13ChemAxon
Refractivity134.68 m3·mol-1ChemAxon
Polarizability53.86 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Drug created on May 20, 2019 09:00 / Updated on March 01, 2020 22:03

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates